![](static/images/product/product-icon-neural-antibodies.png)
NeuroMab™ Anti-HMGB1 BBB Shuttle Antibody,Clone NR3751P
- Host Species:
- Human
- Species Reactivity:
- Human; Mouse
- Applications:
- Block; Inhib; In Vitro; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Relevant Diseases
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Figure 1 Binding kinetics and specificity of human anti-HMG1 antibodies.
HMG1 capture ELISA binding curves of several human anti-HMG1 antibodies comparing capture of native nuclear, necrotic and activated HMG1 showed that S6 and to a lesser extent G4 bound to various forms with different affinities, while S16 did not.
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-1.png)
Figure 2 HMG1 B-box epitope mapping study. HMG1 B-box peptide ELISA binding curves for several human anti-HMG1 antibodies are shown.
The curves indicate binding of S12, S16 and G4 to HMG1 peptide 91-169.
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-2.png)
Figure 3 Human anti-HMG1 antibody inhibits HMG1-stimulated cytokine release from human PBMC
Representative dose-response curves are shown for naturally activated HMG1-stimulated IL-6 cytokine release inhibition of E11, S13, S16, S17, G4, G9, S6, RAGE-Fc and A-box fusion proteins.
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-3.png)
Figure 4 Human anti-HMG1 antibody inhibits HMG1-stimulated cytokine release from human PBMCs.
Representative dose-response curves of recombinant HMG1-stimulated IL-1B, IL-6, and TNF-α release inhibitory activity against several human anti-HMG1 antibodies (G9, S14, G20, S2, S6, and S17) are shown.
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-4.png)
Figure 5. Human anti-HMG1 antibody is protective in a mouse CLP model of sepsis.
Shown are representative survival curves of a mouse CLP model of sepsis comparing treatment with human anti-HMG1 antibody or human isotype control antibody (R3-47).
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-5.png)
Figure 6. Human anti-HMG1 antibody is protective in a mouse CLP model of sepsis.
Shown are representative survival curves of a mouse CLP model of sepsis comparing treatment with human anti-HMG1 antibody or human isotype control antibody (R3-47).
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-6.png)
Figure 7. Synergy between HMG1 and the TLR4 ligand LPS. Left panel) Treatment of human PBMCs with rHMG1 (black bars) stimulated the release of several cytokines (IL-6, MIP-1b, IL-8, and TNF), whereas cells treated with Triton-extracted HMG1 (white bars) did not Stimulate.
Human PBMCs treated with Triton-extracted HMGB1+LPS with anti-TLR4 antibodies or anti-HMG1 antibodies E11, S16, or G4 showed reduced IL-6 release to near background levels, whereas cells treated with isotype control antibodies (R3, IgG2a) did not.
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-7.png)
Figure 8 Anti-HMBG1 antibody reduces induction of TRAP-5b production by HMGB-1 in osteoclast precursor cultures.
Osteoclast precursor cells stimulated with recombinant HMGB (left panel) or synovial fluid fraction containing HMGB1 (right panel) showed increased TRAP-5b activity. Combination treatment with HMGB1 of either origin with G4 or S16 anti-HMGB1 antibodies but not isotype control antibodies did not result in similar increases
![](https://img.creative-biolabs.com/neuros/productImages/NRZP-1022-ZP4006-8.png)
Publications (0)